Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
90
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Predictive Risk Factors for Early Recurrence of Stage pIIIA-N2 Non-Small Cell Lung Cancer

Qiongjie YuDepartment of Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
,
Xuedan DuDepartment of Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
,
Zhen FangDepartment of Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
,
Xiaolu MaoDepartment of Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-6470-0706
ORCID Icon,
Jinting WuDepartment of Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
,
Bin WangDepartment of Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China
&
Wenfeng LiDepartment of Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 8651-8661 | Published online: 18 Nov 2021

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Georg Schlachtenberger, Fabian Doerr, Hruy Menghesha, Andres Amorin, Katja Hoepker, Lars Hagmeyer, Thorsten Wahlers, Khosro Hekmat & Matthias B. Heldwein. (2023) Prognostic impact of lymph node spreading pattern in N2 NSCLC patients. Expert Review of Anticancer Therapy 23:3, pages 319-326.
Read now

Articles from other publishers (1)

Yuanyuan Cheng, Zhe Ye, Yanru Xie, Xuedan Du, Siqi Song, Xiaobo Ding, Chuchu Lin, Bin Wang, Wenfeng Li & Chunhong Zhang. (2023) Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer. Clinical and Translational Oncology.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.